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ABSTRACT  
 
BACKGROUND: Acinetobacter baumannii is an important 
opportunistic nosocomial pathogen.  Class 1 integrons in A. 
baumannii plays a significant role in antibiotic resistance. 
Therefore, this study aimed to investigate the prevalence of 
integrons and antibiotic resistance pattern in A. baumannii isolated 
from clinical samples of Iranian patients. 
METHODS: The Medical Subject Headings (MeSH) and the 
keywords with the help of Boolean operators (“AND” or “OR”) 
were used alone or in combination to conduct the search.  The 
searching process was conducted in the Web of Science,  PubMed, 
Cochrane Library, Scopus, and Google Scholar databases and, also 
Iranian databases.  The search was restricted to relevant English 
and Persian cross-sectional publications reporting the prevalence 
of Int1 in A. baumannii isolated from clinical samples from 1 
January 2000 to 31 December 2018.  The data were analyzed using 
Comprehensive  Meta-Analysis software. Regarding the 
heterogeneity of studies, the random effects model was used. 
Cochrane Q and I2 tests was used to evaluate statistical 
heterogeneity between the studies.  
RESULTS: Fifteen studies were included in the analysis. The 
combined prevalence of class 1 integrons in A. baumannii was 
55.2% (95% CI: 44.8-65.1). The pooled prevalence of MDR A. 
baumannii isolates was 68.1%. The highest resistance belonged to 
Aztreonam, followed by Ciprofloxacin, and Ceftazidime with a 
resistance rate of 97.6%, 92.8%, and 91.6%, respectively. 
Tobramycin was reported as an effective antibiotic. 
CONCLUSIONS: The present study reported an alarmingly high 
prevalence of class 1 Integrons, and MDR isolates of A. baumannii 
recovered from clinical samples that should be considered.  
KEYWORDS: Prevalence, Integrons, Acinetobacter baumannii, 
Pathogen  
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INTRODUCTION  
 
Acinetobacter baumannii is an important aerobic 
Gram-negative opportunistic nosocomial pathogen 
with broad dissemination in the environment (1). 
A range of threating nosocomial infections 
including septicemia, respiratory tract, urinary 
tract infection, and pneumonia, burn wound and 
soft tissue are caused by A. baumannii especially 
in the ICU and burn units (2). In the 21st century, 
A. baumannii emerged as one of the most 
challenging pathogens due to its high adaptation to 
hospital environments (3).  This microorganism 
has been cited among the six top priority 
dangerous drug-resistant bacteria by Infectious 
Diseases Society of America (4), as its prevalence 
is becoming an alarming all over the world(5). 
The epidemiological studies concerning the MDR 
A. baumannii strains show the dissemination of 
different healthcare-associated MDR A. 
baumannii clones worldwide(6). 
Enzyme alteration, the permeability of the 
outer membrane, the mutation in target genes, 
increased expression of efflux pumps and mobile 
genetic elements are the key antibiotic resistance 
mechanisms in A. baumannii microorganism (7).  
Among them, integrons have been known as the 
chief source of resistance genes in Gram-negative 
bacteria including A. baumannii (8).  Integrons are 
DNA elements capable of capturing genes by a 
site-specific recombination mechanism that often 
carries gene cassettes containing antibiotic 
resistance genes (9). Until now, six classes of 
integrons (according to intl gene) have been 
identified, in which classes 1, 2 and 3 showed a 
major role in transferring antibiotic resistance 
genes (10). Class 1 integrons are usually expressed 
in A. baumannii and play a significant role in 
antibiotic resistance and typically encode genes 
for aminoglycoside resistance, β-lactamases, 
Metallo-β-lactamases, and oxacillinases (11). 
Class 2 integrons are carried out inside the 
transposon Tn7 with gene cassettes and attributed 
in conferring resistance to chloramphenicol, 
trimethoprim, aminoglycosides, and streptomycin 
(12). 
To our knowledge, determination of integrons 
prevalence in clinical isolates of A. baumannii 
provides appropriate information concerning the 
pattern of antibiotic resistance in each region. In 
the current study, due to low importance of class 2 
and 3 integrons in antibacterial resistance and 
because of the lack of reporting these integrons in 
studies included in the review, this study aimed to 
investigate the prevalence of integrons and 
antibiotic resistance pattern in A. baumannii 
isolated from clinical samples of Iranian patients 
through systematic review and meta-analysis. 
 
METHODS  
 
Information source and search strategy: The 
Medical Subject Headings (MeSH) and tht 
keywords of “Integrons”, “Int1”, “prevalence”, 
“antibiotic resistance”, “A. baumannii”, “Integron 
prevalence”, and “Iran, with the help of Boolean 
operators (“AND” or “OR”) were used alone or in 
combinations to conduct a broad search.  The 
searching process was done in the Web of 
Science,  PubMed, Cochrane Library, Scopus and 
Google Scholar databases. The search was 
restricted to the papers published in either English 
or Persian from 1 January 2000 to 31 December 
2018.  The studies reporting the prevalence, or 
distribution of Int1 in A. baumannii isolated from 
clinical samples of Iranian patients were included 
in the present review. Correspondingly, the 
Persian equivalents of the keywords were used in 
a comparable strategy to recover Persian articles 
in national databases such as Magiran 
(www.Magiran.com), Irandoc 
(www.irandoc.ac.ir), Iranmedex 
(www.iranmedex.com), and Scientific Information 
Database (www.sid.ir). 
Inclusion and exclusion criteria: All relevant 
English and Persian cross-sectional and cohort 
publications reporting the prevalence of Int1 in A. 
baumannii isolated from clinical samples of 
Iranian patients and cited by databases were 
retrieved and included in the current review.  All 
review forms including (narrative, meta-analysis 
or systematic), prospective studies, congress, case 
reports, meeting, abstracts, studies in languages 
other than English or Persian, editorials, and 
letters to the editors were excluded. Furthermore, 
studies without full text and duplicate publications 
were considered as excluded criteria, too. Two 
independent reviewers completed all these search 
processes to decrease the risk of error and bias.  
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Screening: All recognized articles in both 
languages from the mentioned databases were 
entered into our created file to eliminate 
duplicates. After that, the documents were 
screened by two reviewers (HV and FJJ) 
independently in a few levels. These levels screen 
included title screening, abstract screening and 
lastly full-text screening. At each level, the 
investigators individually assessed the studies, and 
then shared their agreements in the common file.  
Disagreements were resolved by discussion before 
including the studies for the next screening level.  
Dissimilarities between the assessors were argued 
and resolved through agreement.  Where no 
agreement was reached, a third reviewer was 
involved in decision-making. Finally, records 
were assessed for met eligibility and final 
selection. 
Quality assessment: For quality assessment of 
studies methodology was used of the criteria 
mentioned in Critical Appraisal Skills 
Programmed checklists (www.casp-UK). As for 
each study independently, a series of main 
questions were designed. If the relevant 
information was clearly reported, a question was 
scored as ‘yes’. If no, or in case of any doubt, the 
question was marked as ‘no’ or ‘can’t tell’. 
Overall, studies were classified as ‘strong’, 
‘moderate’, or ‘weak’, according to the number of 
questions scored as ‘yes’(13). At last, weak 
studies were removed from the current review. 
Assessing the risk of bias: For quality assessment 
and prevention of the risk of bias, several items 
including design, method, context, findings, and 
analyses of the study, also, interpretations of the 
findings were evaluated. The studies with a key 
flaw in the considered items were excluded. Also,  
it should be noted that any conflicts on the quality 
evaluation or the risk of bias in recording, 
reporting, collection,  contributors, extraction of 
data, confusing factors, and statistical analyses 
were resolved by debates between the two 
assessors or by referring to a third reviewer (14).  
Data extraction: The data were extracted from 
each study by a data extraction form designed for 
the reviewers. The extracted data included (a) the 
first author’s name, (b) publication year, (c) study 
setting, (d) sample size, (e) MDR prevalence, (f) 
and Int1 prevalence.   
Data analysis: The data were analyzed using 
Comprehensive  Meta-Analysis software (Version 
3.3.070). The prevalence was presented by a 95% 
Confidence Interval (CI). Regarding the 
heterogeneity of studies, the random-effects model 
was used for meta-analysis. The Cochrane Q and 
I2 tests were used to evaluate the statistical 
heterogeneity between the  studies.  To estimate 
possible publication bias, quantitative Egger 
weighted  regression test and funnel plot were 
used.  Also, P-value <0.05 was considered as the 
statistical significance threshold. Additionally, the 
asymmetrical distribution of the studies was 
evaluated by Egger’s linear regression test. 
 
RESULTS  
 
Study inclusion: The study selection route is 
abstracted in Figure 1. In brief, 586 relevant 
records were firstly identified in the initial search 
in scientific databases. Two hundred-eleven 
duplicates were removed. Regarding assessing the 
abstracts of the 375 studies, 286 literatures were 
excluded. Then, full texts of 89 studies were 
assessed for eligibility. About 74 articles were 
excluded due to lack of sufficient data and not 
reporting Int1 prevalence. Finally, 15 studies were 
included in the present systematic review and 
meta-analysis. 
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Figure1:  Flow chart diagram of studies included in the present review 
Characteristics of the included studies: As 
presented in Table 1, the selected articles covered 
various areas of Iran (i.e. Center, Northwest, West, 
and South). The prevalence of Int1 in A. 
baumannii isolated from clinical samples of 
Iranian patients varied from 12% to 98.4% (Figure 
2).  The highest prevalence of Int1 was reported in 
a study conducted by Japoni-Nejad et al.  )15( with 
a frequency of 98.4%. The frequency of MDR A. 
baumannii isolates varied from 29% to 100%. As 
shown in Figure 3, the publication bias was 
checked using Funnel plot. Regarding possible 
asymmetrical data distribution in included studies, 
the findings of the Egger’s linear regression test 
did not show any publication bias (P=0.6).   
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Table 1: Characteristics of included studies in clinical specimens. 
  
 
Study Publication 
(Year) 
Location Sample Size MDR 
prevalence 
Int1 prevalence 
Asadollahi (32) 2011 Tehran 40 40(100%) 27(67.5%) 
Taherikalani et al(33) 2011 Tehran 100 - 58 (58% ) 
Asadollahi et al(34) 2012 Tehran 23 - 13(56.5%) 
Farajnia et al(35) 2013 Tabriz 100 80(80%) 74(74 %) 
Mirnejad et al(36) 2013 Tehran 50 41(82%) 15(21%) 
Japoni-Nejad et al(15)  2013 Arak 63 - 62(98.4%) 
Kamalbeik et al(37) 2014 Tehran 42 - 5(12%) 
Azizi et al(38) 2016 Kerman 65 65(100%) 46 (70.8%) 
Goudarzi (39) 2016 Tehran 120 120(100%) 89(74.2%) 
Goudarzi et al(40) 2017 Tehran 105 105(100%) 70(66.7%) 
Eghbalimoghadam(41) 2017 Kermanshah 100 29(29%) 42(42%) 
Mirshekar et al(42) 2018 Tehran 72 - 42(58.3% ) 
Halaji et al(43) 2018 Isfahan 147 - 94(63.9%) 
Eftekhar et al(44) 2018 Tehran 50 - 11 (22%) 
Shaheli et al(45) 2018 Shiraz 83 77 (92.9%)  27 (32.5%)  
 
Table 2: Analysis of prevalence of class 1 integron in P. aeruginosa recovered from Iranian burn patients 
 
Subgroups Number 
of 
studies 
Heterogeneity test Egger’s test Random model 
Prevalence 
(95% CI) 
(%) 
Z P Q      P I2 T  P 
Overall 
effect(Int1) 
15 55.2(44.8-
65.1) 
0.97 0.00 137 0.60 92 0.53 0.37 
MDR 8 68.1(61.9-
73.7) 
5.4 0.00 121.3 0.04 94.2 6 0.04 
 
Overall effects: Regarding the heterogeneity test, 
the values were attained as Q2=137, I2=92, t=0.5 
(P=0.6) for the selected studies. Therefore, 
according to the findings of heterogeneity test, the 
random effects model was used to combine the 
data on prevalence of class 1 integron in A. 
baumannii recovered from clinical samples. The 
combined prevalence of class 1 integrons in A. 
baumannii recovered from clinical samples was 
55.2% (95% CI: 44.8-65.1) (Figure 2). The 
clinical samples were mostly collected from ICU 
and other wards. The pooled prevalence of MDR 
A. baumannii isolates was 68.1% (95% CI: 61.9-
73.7). As presented in Table 3, subgroups analysis 
of antibiotic resistance pattern of A. baumannii 
revealed that the highest combined resistance 
belonged to Aztreonam, followed by 
Ciprofloxacin, and Ceftazidime with a resistance 
rate of 97.6%, 92.8%, and 91.6%, respectively. As 
well as, the least resistance was against 
Tobramycin with a resistance rate of 38.7%. The 
detailed information about antibiotic susceptibility 
is listed in Table 3. 
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Figure 2: Forest plot of the meta-analysis of prevalence of class 1 integron in A. baumannii 
isolated from clinical samples 
 
 
 
Figure 3: Funnel plot of meta-analysis on the prevalence of class 1 integron in A. baumannii recovered 
from clinical samples 
 
 
Study name Statistics for each study Event rate and 95% CI
Event Lower Upper 
rate limit limit Z-Value p-Value
Asadollahi 0.675 0.517 0.801 2.165 0.030
Taherikalani et al 0.580 0.481 0.673 1.593 0.111
Asadollahi et al 0.565 0.363 0.748 0.624 0.533
Farajnia et al 0.740 0.645 0.816 4.588 0.000
Mirnejad et al 0.300 0.190 0.440 -2.746 0.006
Japoni-Nejad et al(15) 0.984 0.896 0.998 4.094 0.000
Kamalbeik et al 0.119 0.050 0.256 -4.201 0.000
Azizi et al 0.708 0.587 0.805 3.242 0.001
Goudarzi 0.742 0.656 0.812 5.057 0.000
Goudarzi et al 0.667 0.571 0.750 3.348 0.001
Eghbalimoghadam 0.420 0.327 0.519 -1.593 0.111
Mirshekar et al 0.583 0.467 0.691 1.408 0.159
Halaji et al 0.639 0.559 0.713 3.336 0.001
Eftekhar et al 0.220 0.126 0.355 -3.707 0.000
Shaheli et al 0.325 0.233 0.433 -3.114 0.002
0.552 0.448 0.651 0.979 0.327
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Table 3: Subgroups analysis for antibiotic resistance in P. aeruginosa isolated from Iranian burn patients 
 
Subgroups Number 
of 
studies 
   Heterogeneity test    Egger’s test     Random model 
Prevalence 
(95% CI) 
(%) 
Z P Q P I2 T P 
Imipenem 14 75.9(63.5-
85.1) 
3.7 0.00 171.5 0.00 92.4 2.1 0.05 
Ciprofloxacin 14 92.8(85.2-
96.6) 
6.2 0.00 161.8 0.00 91.9 2.8 0.01 
Gentamicin 15 72.5(61.3-
81.5) 
3.7 0.00 191.7 0.00 92.6 1.9 0.07 
Amikacin 11 74.2(58.1-
85.6) 
2.8 0.005 197.3 0.00 94.9 1.1 0.26 
Ceftriaxone 7 90.6(73.1-
97.2) 
3.5 0.00 119.5 0.00 94.9 2.5 0.05 
Ceftazidime 11 91.6(80.3-
96.7) 
4.7 0.00 187.9 0.00 94.6 5.7 0.00 
Cefepime 10 56.3(51.3-
61.7) 
2.4 0.00 105.2 0.00 91.4 8.6 0.00 
Piperacillin/ 
tazobactam 
11 59.7(55.6-
63.7) 
4.5 0.00 131.5 0.00 92.3 3.9 0.00 
Aztreonam 2 97.6(95.1-
98.9) 
9.7 0.00 0.5 0.000 0.00 0.00 0.00 
Tobramycin 2 38.7(19.5-
62.2) 
0.94 0.34 16.4 0.00 93.9 0.00 0.00 
Cefotaxime 11 65.6(60.4-
70.4) 
5.6 0.00 106.3 0.00 91.5 3.8 0.00 
 
DISCUSSION  
A. baumannii has an important role in nosocomial 
infection owing to its resistance to different 
classes of antibiotics (16). This resistance is 
caused by different mechanisms. Among them, 
Integrons plays an important role, and spreading 
of antibiotic resistance genes via them is 
problematic in treatment of infections caused by 
this microorganism (4,17).  The findings of the 
current study showed the combined prevalence of 
55.2% of class 1 integrons in A. baumannii 
recovered from clinical specimens. The pooled 
prevalence of MDR A. baumannii isolates was 
68.1%. The prevalence of class 1 integrons are 
increased all over the world. In aagreement with 
our findings, other reports from Italy (18), and 
China (19) showed the prevalence 44% and 71%, 
respectively. However, Javier Ariza, et al. 
reported a lower prevalence (25%) from Spain 
(20). 
This high prevalence of integron class 1 in A. 
baumannii isolates is attributed to several reasons 
such as inappropriate use of antibiotics for 
treatment of A. baumannii infections, and 
consequently, the high expression of gene 
cassettes containing integrons class 1 and, 
secondly, the ability of integrons to acquire new 
gene cassettes lead to disseminating antibiotic 
resistance among clinical isolates. Finally, failure 
in establishment of a national surveillance 
program as part of the Global Strategy for 
Containment of Antimicrobial Resistance in 
medical centers leads to survival of MDR A. 
baumannii isolates carrying integron and 
spreading of resistance integrons among other A. 
baumannii isolates (21). Class 1 integrons are 
prevalent as compared to the other classes of 
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integrons possibly due to the location of class 1 
integrons on genetic elements such as conjugative 
plasmids and transposons (22). As stated in the 
present review, the pooled prevalence of MDR A. 
baumannii isolates was 68.1%.  
This subject leads to MDR A. baumannii 
isolates carrying integron and spreading of 
resistance integrons among other A. baumannii 
isolates. Inconsistent with the present review, 
another review from Iran showed that the 
frequency of MDR A. baumannii isolates 
increased from 50% in 2001–2007 to 74% in 
2010–2015, with a mean prevalence of 71% (23). 
Prolonged hospital stay especially in Intensive 
Care Unit (ICU), receiving of ventilator, recent 
surgery, medical interventions, colonization 
pressure, and use of overdose of antibiotics such 
as Carbapenems, Colistin, invasive procedures, 
underlying diseases are the main risk factors for 
colonization or infection with MDR A. baumannii 
isolates (24).  To our knowledge, Imipenem acts 
as a choice drug in the treatment of infections 
caused by A .baumannii (5). As shown in the 
results section, the resistance rate against 
Imipenem was reported as 75.9%. The resistance 
against Imipenem is increased worldwide as some 
studies from other countries including Pakistan 
(100%), Turkey (98%), United Arab Emirates 
(76%) and Saudi Arabia (63%) reported the same 
pattern (25-28).  In confirmation of our results, a 
study from Taiwan revealed that MDR-AB 
isolates carrying integrons were significantly more 
resistant to almost all antibiotics used than non-
integron-carrying isolates (19). In geographical 
districts including China and Spain, Integron-
carrying MDR-AB isolates have been reported, 
too (29,30). Their results showed that MDR-AB 
strains carrying different gene cassettes including 
different integron cassette types 2, 3, 4 and 6 have 
been found to have similar multidrug resistance 
patterns, indicating the correlation of integrons 
and multidrug resistance. Then, we can conclude 
that the high MDR isolates in the current review 
can possibly be attributed to the existence of class 
1 integrons. Clinical isolates of A. baumannii all 
over the world share different resistance 
mechanisms with other bacterial genera (30). 
Therefore, the high prevalence of the Integrons in 
clinical isolates of A. baumannii from Iran can be 
very worrying, and A. baumannii isolates will not 
respond to existing antibiotics any more and cause 
transmission of resistance through the Integrons.  
Establishing a national surveillance program as 
part of the Global Strategy for Containment of 
Antimicrobial Resistance in medical centers is 
critical (31). When antibiotics become ineffective 
due to bacterial resistance, implement, and 
evaluate new specific containment interventions is 
crucial to collect specific information regarding 
MDR isolates of A. baumannii. 
The present study reported alarming high 
prevalence of class 1 Integrons and MDR isolates 
of A. baumannii are recovered from clinical 
samples that should be considered.  
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